{"entity":{"id":"nct07462143","kind":"trial","name":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 2/3 trial of RC148, CAPOX in colorectal cancer, run by RemeGen Co., Ltd., now recruiting.","summary":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer is a phase 2/3 interventional study registered as NCT07462143 by RemeGen Co., Ltd., with 80 participants planned, started 2026-05-12 and due to reach its primary completion in 2027-05-12. Interventions recorded: RC148 (Dose 1) plus Capecitabine and Oxaliplatin, RC148 (Dose 2) plus Capecitabine and Oxaliplatin. Conditions listed: Colorectal (Colon or Rectal) Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07462143","url":"https://clinicaltrials.gov/study/NCT07462143"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["rc148","capox"],"companies":["remegen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07462143","phase":"2/3","setting":"A Randomized, Multicenter, Phase Ⅱ/Ⅲ Study of RC148 Combined With Chemotherapy Versus Bevacizumab Combined With Chemotherapy as First-line Treatment for Unresectable or Metastatic Colorectal Cancer","sponsor":"RemeGen Co., Ltd.","enrolled":80,"outcomes":[]},"route":"/trials/nct07462143/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"rc148","kind":"drug","name":"RC148","route":"/drugs/rc148/"}],"company":[{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/"}]}}